The expression of both NRF1 antibodies showed a significant NRF1 decrease from benign to dysplastic naevi (p < 0.001 and p = 0.034, Supplementary , Figures 1(a) and 3) and from naevi to primary melanoma, as well as to metastatic lesions (p < 0.001, Figures 1(a) and 3) [20]. This evidence concerns the gene NRF1 and melanoma.